Attention A T users. To access the menus on this page please perform the following steps. 1. Please switch auto forms mode to off. 2. Hit enter to expand a main menu option (Health, Benefits, etc). 3. To enter and activate the submenu links, hit the down arrow. You will now be able to tab or arrow up or down through the submenu options to access/activate the submenu links.

Viral Hepatitis


Quick Links

Veterans Crisis Line Badge
My healthevet badge
EBenefits Badge

Hepatitis C Treatment Considerations

for Veterans and the Public

Chronic Hepatitis C Virus (HCV) Infection: Treatment Considerations


For the full PDF version, click here


This revision (September 22, 2016) incorporates updates to treatment regimens for chronic hepatitis C virus (HCV) infection, genotype 1, 2, 3, or 4. Updated sections include:

  • A revised table in "Interpretation of Resistance-Associated Polymorphisms"
  • A new table for "Genotype 1-Infected Patients Who Have Failed Treatment with DAA-Based Therapy"
  • Updates on drug-drug interactions to provide clinicians with guidance on the concomitant use of HCV drugs and other drugs, including HIV antiretroviral agents (Table 25 and Table 26)
  • Information on HCV resistance genotyping and sample reports can be found in Appendices B and C

The Panel continues to recommend that HIV/HCV-coinfected patients receive the same HCV antiviral regimens as HCV-monoinfected patients except in situations where ledipasvir/sofosbuvir is being considered, in which case a 12-week regimen should be used.